Yazar "Dikme, Gürcan" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim
    Öğe
    Comparison of allogeneic stem cell transplantation results from related or unrelated donors in beta-thalassemia major
    (Nature Publishing Group, 2019) Aydoğdu, Selime; Mergen, Azize; Adaklı Aksoy, Başak; Çokluk, Mila N.; Dikme, Gürcan; Erol Cipe, Funda; Fışgın, Tunç; Bozkurt, Ceyhun
    Although there have been significant improvements with conventional therapies in beta thalassemia major, hematopoietic stem cell transplantation is only curative therapy. Related donors are preferred to diminish transplant risks. In lack of identical related donor, identical unrelated donors are second best choice. In this study, thalassemia major patients transplanted from unrelated donors (MUD) were compared with thalassemic patients transplanted from relative donor (MRD) retrospectively.
  • Küçük Resim
    Öğe
    Comparison of turkish stem cell coordination center (TURKOK) with Istanbul university bone marrow bank (TRIS); A single center experience in match unrelated donors
    (Nature Publishing Group, 2019) Mergen, Azize; Aydoğdu, Selime; Adaklı Aksoy, Başak; Savcı, Yunus Emre; Dikme, Gürcan; Erol Cipe, Funda; Bozkurt, Ceyhun; Fışgın, Tunç
    Match family donors are the preferable options in allogenic stem cell transplant. However, in the absence of donor relatives match unrelated donors have been an option. In this study, the donor screening, transplant preparation phases of Turkish Stem Cell Coordination Center (TURKOK) and the İstanbul University Bone Marrow Bank (TRIS), were compared.
  • Küçük Resim
    Öğe
    Donor lymphocyte infusion administrations after allogeneic stem cell transplantations in pediatrics: a single center experience
    (Nature Publishing Group, 2019) Aydoğdu, Selime; Mergen, Azize; Adaklı Aksoy, Başak; Akbay, Hazal S.; Erol Cipe, Funda; Dikme, Gürcan; Fışgın, Tunç; Bozkurt, Ceyhun
    Loss of chimerism is one of the major problems after allogeneic stem cell transplantation(SCT). Donor- lymphocyte infusions(DLI) are used as a treatment after taper or stopping immunosuppression. In this study, DLI experience in 20 patients with loss of chimerism after SCT due to various benign and malign hematological diseases was presented.
  • Küçük Resim
    Öğe
    Extracorporeal photopheresis treatment for steroid resistant graft versus host disease in pediatrics: single center experience
    (Nature Publishing Group, 2019) Aksoy, Başak Adaklı; Savcı, Yunus Emre; Mergen, Azize; Aydoğdu, Selime; Dikme, Gürcan; Bozkurt, Ceyhun; Fışgın, Tunç
    Background: Steroid resistant graft vs host disease (GVHD) is de?ned as unresolved or worsened symptomatology of GVHD at day 14 despite effective immunosuppression with steroid therapy. Second line immunosuppressive agents, extracorporeal photopheresis (ECP) and/or mesenchymal stem cell therapies are being tried as salvage therapy.
  • Küçük Resim
    Öğe
    Hit three birds with one stone: successful stem cell transplantation from one family donor to three siblings
    (Nature Publishing Group, 2019) Aksoy, Başak Adaklı; Aydoğdu, Selime; Dikme, Gürcan; Mergen, Azize; Bozkurt, Ceyhun; Fışgın, Tunç
    Background: Thalassemia major is a single gene related hereditary hemoglobinopaty required life long regular transfusions with chelation therapies. Stem cell transplantation is the only curative treatment of the disease. Three sibling thalassemia patients 13,4 and 3 years old were succesfully transplanted from their only donor,fully matched seventeen years old sister at our center.
  • Küçük Resim
    Öğe
    Primary immunodeficiencies: HSCT experiences of a single center in Turkey
    (WILEY, 2021) Erol Çipe, Funda; Adaklı Aksoy, Başak; Aydoğdu, Selime; Dikme, Gürcan; Kıykım, Ayca; Aydoğmus, Çiğdem; Yücel, Esra; Bozkurt, Ceyhun; Fışgın, Tunç
    Background Primary immunodeficiency diseases (PID) are characterized by the occurrence of frequent infections and are caused by many genetic defects. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment option for the majority of PID. As a Pediatric Hematology-Oncology-Immunology Transplantation Unit, we wanted to present our HSCT experience regarding treatment of primary immunodeficiency diseases. Methods 58 patients were included in the study between January 2014 and June 2019. We searched 9/10 or 10/10 matched-related donor (MRD) firstly, in the absence of fully matched-related donor. We screened matched unrelated donor (MUD) from donor banks. MRD was used in 24 (41.3%) patients, MUD in 20 (34.4%) patients, and haploidentical donors in 14 (24.1%) patients. Demographic data, HSCT characteristics, and outcome were evaluated. While 16 patients had severe combined immunodeficiency (SCID), the remaining was non-SCID. Results Of the 58 patients, 38 were male and 20 were female. Median age at transplantation was 12 months (range: 2.5-172 months). Combined immunodeficiencies consisted 67.2% of patients. Mean follow-up time was 27 months (6 months-5 years). Median neutrophil, lymphocyte, and thrombocyte engraftment days were similar in comparison of both donor type and stem cell source. The most common complication was acute GvHD in 15 (25.8%) patients. In total, five patients (31%) belonging to the SCID group and 10 patients (23.8%) belonging to the non-SCID group died. Our total mortality rate was 15 (25.8%) in all patients. Conclusions We would like to present our HSCT experiences as a pediatric immunology transplantation center. Existing severe infections before transplantation period, BCGitis, and CMV are important issues of transplantation in Turkey. However, the follow-up time is shorter than some studies, our results regarding complications and survival are similar to previous reports.